4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Rhea-AI Summary
4D Molecular Therapeutics (NASDAQ:FDMT), a late-stage biotechnology company, announced its participation in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. The company's management will engage in a fireside chat on Wednesday, August 13, 2025, at 2:30 p.m. ET.
The presentation will be available via webcast, and management will be available for one-on-one meetings. An archived recording of the webcast will be accessible for up to one year on the company's investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – FDMT
On the day this news was published, FDMT declined 5.29%, reflecting a notable negative market reaction. Argus tracked a trough of -2.2% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $15M from the company's valuation, bringing the market cap to $265M at that time.
Data tracked by StockTitan Argus on the day of publication.
EMERYVILLE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will participate in a fireside chat at the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference. Members of the management team will also be available for one-on-one meetings.
H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
| Presentation Date: | Wednesday, Aug 13, 2025 |
| Presentation Time: | 2:30 p.m. ET |
| Webcast Link: | Webcast |
An archived copy of the webcast will be available for up to one year on the “Investors” section of the 4DMT website at https://ir.4dmoleculartherapeutics.com/events.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) with a single, safe, intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts:
Media:
Jenn Gordon
dna Communications
Media@4DMT.com
Investors:
Julian Pei
Head of Investor Relations and Strategic Finance
Investor.Relations@4DMT.com
FAQ
When is 4D Molecular Therapeutics (FDMT) presenting at the H.C. Wainwright Ophthalmology Conference?
Where can I watch the FDMT presentation at the H.C. Wainwright Conference?
What type of presentation will FDMT give at the H.C. Wainwright Conference?
How long will FDMT's H.C. Wainwright Conference presentation be available to view?
